Zelgen

Zelgen is a leading clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery, development, and commercialization of innovative medicines in oncology, hematology, and autoimmune diseases. The company has successfully brought two products to market in China: donafenib (Zepaton) for hepatocellular carcinoma and thyroid cancer, and a recombinant human thrombin for surgical hemostasis. Zelgen maintains a diverse pipeline featuring several late-stage assets, most notably jackitinib, a multi-kinase JAK inhibitor being evaluated for myelofibrosis and various dermatological conditions. The company utilizes three core technology platforms focused on small molecules, recombinant proteins, and multi-specific antibodies to drive its R&D engine. Zelgen is listed on the Shanghai Stock Exchange's STAR Market and operates integrated manufacturing and R&D facilities to support its global expansion goals.